Boston Scientific to Host Investor Event on March 28, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BSX?
Source: Newsfilter
- Investor Event Details: Boston Scientific will host an investor event on March 28, 2026, at 6:30 p.m. ET to discuss key clinical data presented at the 75th Annual Scientific Session of the American College of Cardiology, aimed at enhancing investor confidence in the company's future growth.
- Executive Leadership: The event will be co-hosted by Dr. Kenneth Stein, Senior Vice President and Global Chief Medical Officer, Dr. Brad Sutton, Chief Medical Officer of AF Solutions, and Dr. Michael R. Jaff, Vice President and Chief Medical Officer of Vascular Therapies, ensuring a high level of expertise and authority.
- Live Webcast and Replay: The event will be accessible via live webcast, with a replay available approximately one hour after the event concludes, allowing investors who cannot attend live to stay informed, thereby enhancing transparency and investor relations.
- Company Overview: Boston Scientific has over 45 years of experience in the medical technology sector, committed to transforming lives through innovative technologies that improve patient health globally, offering a broad range of high-performance solutions to address unmet patient needs and reduce healthcare costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 71.900
Low
94.00
Averages
108.14
High
132.00
Current: 71.900
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Expands Buyback Authorization Amid Legal Challenges
- Increased Financial Flexibility: In late February 2026, Boston Scientific entered into a $3.00 billion revolving credit agreement maturing in 2031, significantly enhancing the company's capital flexibility to support growth in cardiovascular and electrophysiology therapies.
- Expanded Buyback Authorization: The board increased the share repurchase authorization to $5.00 billion, reflecting a commitment to capital discipline that could bolster investor confidence following stock pullbacks, despite ongoing legal risks related to electrophysiology litigation.
- Legal Challenges Impact: Boston Scientific is currently facing multiple securities class action lawsuits tied to its U.S. electrophysiology segment, which may exert pressure on its operations and financial performance, necessitating investor attention on how these issues could influence the company's investment narrative.
- Future Outlook: The company projects revenues of $25.4 billion and earnings of $4.8 billion by 2028, indicating potential in high-margin technology investments and acquisition integrations, although execution risks remain a concern in the near term.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for alleged violations of the Securities Exchange Act during stock transactions from July 23, 2025, to February 3, 2026, with investors having until May 4, 2026, to seek lead plaintiff status, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported Q4 2025 earnings with a net income of $672 million and EPS of $0.45, which, despite year-over-year growth, fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the electrophysiology market, leading to a decline in its market share and limiting growth potential, which could negatively impact investor confidence.
- Legal Representation Process: Robbins Geller Rudman & Dowd LLP, as the lead law firm, emphasizes that any investor who purchased Boston Scientific stock during the class period can apply to be the lead plaintiff, indicating the potential financial liabilities and the importance of protecting investor rights in the ongoing legal proceedings.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management made overwhelmingly positive statements while concealing the true state of its U.S. EP segment's growth, which has severely undermined investor confidence and negatively impacted shareholder interests.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that fell short of expectations, particularly in U.S. EP sales, leading to guidance for fiscal 2026 that was well below market expectations, exacerbating investor anxiety about the company's future.
- Stock Price Plunge: Following the disappointing earnings announcement, Boston Scientific's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a dramatic 17.6% decline in just one day, reflecting the market's pessimism about the company's outlook.
See More
Boston Scientific Shareholder Class Action Reminder
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) stock between July 23, 2025, and February 3, 2026, alleging the company misled investors regarding revenue projections.
- Revenue Projection Missteps: The complaint states that Boston Scientific claimed its electrophysiology (EP) market growth would be double that of the market, yet new competitors have entered, diminishing the company's market share and limiting growth potential.
- Stock Price Plunge: Following the February 4, 2026, earnings report, which revealed disappointing U.S. EP sales, Boston Scientific's stock price plummeted over 17%, from $91.62 per share on February 3 to $75.50, reflecting market disappointment in the company's outlook.
- Shareholder Action Guide: Shareholders wishing to serve as lead plaintiffs must submit their papers by May 4, 2026; Robbins LLP offers contingency-based representation, meaning shareholders incur no fees or expenses.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting the company and its officers, which involves all securities purchasers between July 23, 2025, and February 3, 2026, highlighting investor concerns over financial transparency.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, severely undermining investor confidence in the company's future.
- Market Reaction: As the company faces adverse trends such as declining procedure volumes, increased competitive pressures, and regulatory reimbursement challenges, investor losses may escalate, reflecting a pessimistic outlook on Boston Scientific's future performance.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, indicating that legal action may provide a pathway for recovery of losses, further emphasizing the need for corporate governance and transparency.
See More
Boston Scientific Expands Buyback Authorization Amid Legal Challenges
- Increased Financial Flexibility: In late February 2026, Boston Scientific entered into a $3.00 billion revolving credit agreement maturing in 2031, significantly enhancing the company's capital flexibility to support growth in cardiovascular and electrophysiology therapies.
- Expanded Buyback Authorization: The board increased the share repurchase authorization to $5.00 billion, reflecting a commitment to capital discipline that could bolster investor confidence following stock pullbacks, despite ongoing legal risks related to electrophysiology litigation.
- Legal Challenges Impact: Boston Scientific is currently facing multiple securities class action lawsuits tied to its U.S. electrophysiology segment, which may exert pressure on its operations and financial performance, necessitating investor attention on how these issues could influence the company's investment narrative.
- Future Outlook: The company projects revenues of $25.4 billion and earnings of $4.8 billion by 2028, indicating potential in high-margin technology investments and acquisition integrations, although execution risks remain a concern in the near term.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for alleged violations of the Securities Exchange Act during stock transactions from July 23, 2025, to February 3, 2026, with investors having until May 4, 2026, to seek lead plaintiff status, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported Q4 2025 earnings with a net income of $672 million and EPS of $0.45, which, despite year-over-year growth, fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the electrophysiology market, leading to a decline in its market share and limiting growth potential, which could negatively impact investor confidence.
- Legal Representation Process: Robbins Geller Rudman & Dowd LLP, as the lead law firm, emphasizes that any investor who purchased Boston Scientific stock during the class period can apply to be the lead plaintiff, indicating the potential financial liabilities and the importance of protecting investor rights in the ongoing legal proceedings.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management made overwhelmingly positive statements while concealing the true state of its U.S. EP segment's growth, which has severely undermined investor confidence and negatively impacted shareholder interests.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that fell short of expectations, particularly in U.S. EP sales, leading to guidance for fiscal 2026 that was well below market expectations, exacerbating investor anxiety about the company's future.
- Stock Price Plunge: Following the disappointing earnings announcement, Boston Scientific's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a dramatic 17.6% decline in just one day, reflecting the market's pessimism about the company's outlook.
See More
Boston Scientific Shareholder Class Action Reminder
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) stock between July 23, 2025, and February 3, 2026, alleging the company misled investors regarding revenue projections.
- Revenue Projection Missteps: The complaint states that Boston Scientific claimed its electrophysiology (EP) market growth would be double that of the market, yet new competitors have entered, diminishing the company's market share and limiting growth potential.
- Stock Price Plunge: Following the February 4, 2026, earnings report, which revealed disappointing U.S. EP sales, Boston Scientific's stock price plummeted over 17%, from $91.62 per share on February 3 to $75.50, reflecting market disappointment in the company's outlook.
- Shareholder Action Guide: Shareholders wishing to serve as lead plaintiffs must submit their papers by May 4, 2026; Robbins LLP offers contingency-based representation, meaning shareholders incur no fees or expenses.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, targeting the company and its officers, which involves all securities purchasers between July 23, 2025, and February 3, 2026, highlighting investor concerns over financial transparency.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, severely undermining investor confidence in the company's future.
- Market Reaction: As the company faces adverse trends such as declining procedure volumes, increased competitive pressures, and regulatory reimbursement challenges, investor losses may escalate, reflecting a pessimistic outlook on Boston Scientific's future performance.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, indicating that legal action may provide a pathway for recovery of losses, further emphasizing the need for corporate governance and transparency.
See More
